-Unique microthin cuff designed to reduce micro-aspiration, a known cause
ROSWELL, Ga., May 20 /CNW/ -- Kimberly-Clark Health Care announced the
presentation of data related to the Kimberly-Clark Microcuff Adult
Endotracheal (ET) Tube at the American Thoracic Society (ATS) meeting in San
Diego this week. The study, conducted at the University of Michigan, Ann
Arbor, demonstrated a 43 percent reduction in the incidence of
ventilator-associated pneumonia (VAP) when using the Microcuff ET Tube.
"Micro-aspiration is a known cause of VAP, and we believe the use of a
thin-cuffed ET tube, such as Microcuff, can significantly reduce this risk,"
said lead investigator Dr. Robert Hyzy, associate professor of internal
medicine and director of the Critical Care Medicine Unit at the University of
Michigan Health System in Ann Arbor, Mich. "VAP is a complex issue, and our
study was designed to be very comprehensive. We implemented Microcuff
house-wide to ensure virtually every intubated patient in our ICUs received
the tube for a 12-month period and then compared VAP rates to those of the
prior 12 months."
The results found that with the use of the Microcuff ET Tube, the
incidence of VAP was reduced 43 percent to 2.8 episodes per 1000 vent days
versus 5.3 episodes per 1000 days with a standard ET tube.
"The results of this study are an important advance in the prevention of
VAP," said Lynne Kelley, M.D., vice president and senior medical director for
Kimberly-Clark. "Kimberly-Clark is committed to the fight against
health-care-associated infections and believes technologies, such as
Microcuff, can help save patients' lives and reduce costs to our health care
system, which is increasingly important during this economically challenging
The Microcuff ET Tube has a unique microthin polyurethane cuff designed
to minimize the leakage of potentially infectious secretions into the lungs,
which can cause serious complications such as VAP. The microthin cuff has the
added clinical benefit of effectively sealing the trachea at lower cuff
pressures, thereby reducing the risk of tracheal trauma.
Ventilator-associated pneumonia is one of the top three infection
concerns of clinicians today; it may account for up to 60 percent of all
deaths from health-care-associated infections (HAIs) in the United States.
Approximately 8 to 28 percent of critical care patients develop VAP, which has
a mortality rate of 20 to 33 percent and is estimated to generate an increased
cost of $20,000 to $40,000 per incident. A leading cause of VAP is
micro-aspiration of potentially infectious secretions through gaps in the
endotracheal tube cuff. The cuff seal is the final barrier that protects the
lungs from aspiration of potentially infectious oropharyngeal secretions.
To learn more about the Kimberly-Clark Microcuff Endotracheal tubes,
Kimberly-Clark in the Health Care Environment
Around the world, medical professionals turn to Kimberly-Clark for a wide
portfolio of solutions that improve the health, hygiene and well-being of
their patients and staff. As part of their healing mission, caregivers rely on
Kimberly-Clark to deliver clinical solutions and educational resources that
they can depend on to prevent, diagnose and manage a wide variety of
health-care-associated infections. This more than $1 billion global enterprise
of Kimberly-Clark Corporation holds the No. 1 or No. 2 market share position
in several categories, including infection control solutions, surgical
solutions, pain management and digestive health. And throughout the care
continuum, patients and staff alike trust Kimberly-Clark medical supplies and
devices, KLEENEX tissues, Kimberly-Clark professional skin care products and
SCOTT towels for day-to-day needs. For more information, visit
For further information:
For further information: Dave Dickson of Kimberly-Clark Corporation,
+1-972-281-1481, email@example.com Web Site: http://www.kimberly-clark.com